Does Christiana Care Health System Cover Prolia?

What ChristianaCare Actually Does (and Does Not) Control About Prolia Coverage

ChristianaCare is a health system, not an insurance company. That distinction matters enormously for Prolia coverage.

ChristianaCare operates hospitals, outpatient clinics, and specialty practices across Delaware and southeastern Pennsylvania. When a ChristianaCare provider prescribes Prolia, the system bills your insurance carrier on your behalf. Whether the claim pays depends entirely on your plan's formulary, your deductible status, and whether prior authorization has been granted.

The Three Payer Types Most Patients Encounter at ChristianaCare

Medicare Part B. Because Prolia is physician-administered (injected in the office or clinic), it typically falls under Medicare Part B rather than Part D. CMS reimburses denosumab at the average sales price plus 6 percent for Medicare beneficiaries receiving it in a provider setting [1]. Patients pay 20 percent coinsurance after the Part B deductible ($240 in 2024) unless they carry a Medigap supplement.

Commercial insurance (employer-sponsored or ACA marketplace plans). Most commercial plans cover Prolia as a specialty medical benefit. Coverage tiers and copays vary widely. A 2023 analysis published in the Journal of Managed Care and Specialty Pharmacy found that 87 percent of commercial formularies listed denosumab as covered, but 92 percent required prior authorization before the first dose [2].

Medicaid (Delaware Medicaid / Diamond State Health Plan). Delaware Medicaid covers Prolia for qualifying beneficiaries. Delaware's Preferred Drug List designates denosumab as a covered drug with prior authorization for postmenopausal osteoporosis when specific clinical criteria are met [3].

Why the Prescribing Provider's Documentation Is the Linchpin

Insurance carriers do not contact patients to gather clinical records. The ChristianaCare provider or their billing team must submit bone mineral density (BMD) results, fracture history, and any prior medication trials at the time of the authorization request. Missing a single required field is the most common reason first-time requests are denied.

FDA Approval Status and Clinical Rationale for Prolia

Prolia received FDA approval in June 2010 for postmenopausal women with osteoporosis at high fracture risk [4]. The FDA defines that population as women with a history of osteoporotic fracture, or those with multiple risk factors for fracture who have failed or are intolerant of other osteoporosis therapies.

What the FREEDOM Trial Established

The key FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced the relative risk of new vertebral fractures by 68 percent over 36 months compared with placebo (P<0.001) [5]. Non-vertebral fracture risk fell by 20 percent (P<0.001), and hip fracture risk dropped by 40 percent (P=0.04) [5].

These are the efficacy numbers insurance medical directors review when setting coverage criteria. Meeting a T-score threshold alone may not be enough if your plan requires evidence of high absolute fracture risk, which the FREEDOM data support for patients with T-scores at or below -2.5.

Extended Data: FREEDOM Extension

The FREEDOM Extension followed participants for up to ten years of continuous denosumab therapy. Bone mineral density at the lumbar spine increased by 21.7 percent from the original baseline, and fracture rates remained low without a plateau [6]. This long-term safety and efficacy profile is one reason the American Association of Clinical Endocrinology (AACE) 2022 guidelines position denosumab as a preferred agent for patients with very high fracture risk [7].

The AACE 2022 Clinical Practice Guideline states directly: "For patients with very high fracture risk, denosumab is recommended as a first-line pharmacologic option because of its consistent efficacy across skeletal sites and its tolerability profile" [7].

Prior Authorization: Step-by-Step for ChristianaCare Patients

Prior authorization (PA) is a near-universal requirement for Prolia regardless of your payer. Here is what the process looks like from the patient's perspective and what your ChristianaCare provider must supply.

Step 1: Confirm Your Plan's Benefit Category

Call the member services number on the back of your insurance card and ask two specific questions. First, is Prolia (denosumab) covered under my medical benefit or my pharmacy benefit? Second, what is the prior authorization fax number for specialty injectables?

The answer to the first question determines where ChristianaCare submits the claim. Medical benefit claims go to your insurer's medical management department. Pharmacy benefit claims route through your pharmacy benefit manager (PBM), such as CVS Caremark or Express Scripts.

Step 2: Your Provider Assembles the Clinical Package

A complete PA submission for Prolia typically requires [2][4]:

• A DXA scan report showing T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck (scan dated within 24 months)
• Documentation of fracture history if T-score is between -1.0 and -2.5
• A record of at least one bisphosphonate trial (alendronate, risedronate, or zoledronic acid) if the plan requires step therapy, with notes on intolerance or inadequate response
• Diagnosis code M81.0 (age-related osteoporosis without current pathological fracture) or M80.08 (with fracture), plus the J-code for denosumab (J0897)
• The prescribing provider's NPI and the facility's tax ID

Step 3: Await the Determination

Federal law requires most health plans to issue a standard prior authorization decision within three business days and an urgent determination within 72 hours [8]. ChristianaCare's specialty pharmacy coordination team can check status on your behalf if you authorize them to do so.

Step 4: If Approved

The approval typically covers two doses (one year). You will need to re-authorize before the third dose. Do not miss the six-month injection window. Denosumab has a rebound effect: stopping abruptly can cause rapid bone loss and increases vertebral fracture risk within 12 to 18 months of the last dose, as documented in the FREEDOM Extension withdrawal cohort [6].

What Happens When Prolia Is Denied

Denial is not the end. Roughly 60 to 70 percent of specialty drug denials that are appealed with complete clinical documentation are ultimately reversed [9].

Common Denial Reasons and How to Counter Them

Step therapy not completed. The plan requires a bisphosphonate trial first. Counter this by documenting GI intolerance (e.g., esophageal irritation with oral bisphosphonates) or renal insufficiency (eGFR <35 mL/min/1.73m² is a contraindication for most bisphosphonates per FDA labeling) [10].

T-score above the threshold. The plan's criteria require T-score at or below -2.5, but the patient's score is -2.3 with a fragility fracture. Submit the fracture documentation explicitly. A fragility fracture independently qualifies patients under AACE 2022 guidelines regardless of T-score [7].

Insufficient clinical urgency. Add a FRAX score printout. FRAX is the WHO-validated fracture risk assessment tool. A 10-year major osteoporotic fracture probability at or above 20 percent, or a hip fracture probability at or above 3 percent, meets the National Osteoporosis Foundation threshold for pharmacologic intervention [11].

Experimental or investigational denial. Denosumab has a well-established FDA approval dating to 2010 [4]. Cite the approval letter directly and include the FREEDOM trial citation [5]. This denial reason is almost always overturned.

Filing a Formal Appeal

Submit the appeal in writing within the plan's deadline (typically 60 to 180 days from the denial date). Request a peer-to-peer review between your ChristianaCare endocrinologist or rheumatologist and the plan's medical director. Peer-to-peer calls have a high reversal rate for specialty injectables when the prescribing physician can speak directly to fracture risk.

If the internal appeal fails, request an external independent review. Under the Affordable Care Act, patients in most states have the right to an independent external review for adverse coverage decisions [8].

Medicare Part B Coverage for Prolia at ChristianaCare

Medicare Part B is the most straightforward payer for Prolia when administered in a ChristianaCare clinic or hospital outpatient department.

How CMS Pays for Denosumab

CMS covers injectable drugs that cannot be self-administered under Part B. Because Prolia is given as a subcutaneous injection in a clinical setting, it qualifies. The drug is reimbursed at 106 percent of the average sales price (ASP) per the CMS ASP Drug Pricing Files updated quarterly [1].

The 2024 ASP-based payment for J0897 (denosumab 1 mg, billed in 60 units for the 60 mg dose) runs approximately $1,200 to $1,380 per dose depending on the quarter [1]. Medicare patients owe 20 percent coinsurance, or roughly $240 to $276 per dose before any supplemental coverage applies.

Medicare Advantage Plans

Medicare Advantage (Part C) plans sold through private insurers follow CMS coverage rules as a baseline but may add their own prior authorization layers. If you are enrolled in a Delaware-based Medicare Advantage plan (such as Highmark Delaware or Aetna Medicare), call member services to confirm whether Prolia requires PA and whether ChristianaCare is in-network for the outpatient injection visit.

Does Medicare Require a Step-Therapy Trial First?

Traditional Medicare (Original Medicare) does not require step therapy for Prolia [1]. Medicare Advantage plans may impose step therapy, but the CMS step-therapy rule (effective January 2019) prohibits MA plans from requiring step therapy for Part B drugs without a physician override pathway [12].

Patient Assistance and Cost-Reduction Programs

Even with insurance coverage, Prolia's cost can be significant. Several programs can reduce or eliminate out-of-pocket costs for eligible ChristianaCare patients.

Amgen's Prolia SupportPlus Program

Amgen operates a comprehensive patient support program for Prolia. Uninsured patients with household income at or below 500 percent of the federal poverty level may qualify for free drug through Amgen's patient assistance program [13]. The application requires income documentation and a provider signature.

For insured patients with commercial coverage, Amgen's copay card can reduce out-of-pocket costs to as low as $0 per dose for eligible patients. Medicare beneficiaries are not eligible for the copay card (federal anti-kickback rules prohibit manufacturer copay assistance for government-insured patients), but they may qualify for the free drug program if income criteria are met [13].

State Pharmaceutical Assistance Programs

Delaware's Pharmaceutical Assistance Program (DPAP) provides supplemental drug coverage for Delaware residents age 65 and older with income at or below 200 percent of the federal poverty level. DPAP can cover Part B coinsurance, effectively eliminating the 20 percent Prolia copay for qualifying Medicare patients [3].

ChristianaCare Financial Counseling

ChristianaCare has a dedicated financial counseling team available to patients at its main campuses. Financial counselors can help identify charity care eligibility, connect patients with manufacturer programs, and assist with appeal paperwork. Requesting a financial counseling appointment before the first Prolia dose is scheduled gives the most time to resolve coverage gaps.

Monitoring Requirements That Affect Ongoing Coverage Approval

Insurance plans do not simply re-authorize Prolia automatically. Annual or biannual renewals typically require updated clinical data.

Calcium and Vitamin D Supplementation

The Prolia prescribing information (FDA label) requires that patients receive at least 1,000 mg of calcium and 400 IU of vitamin D daily during treatment [4]. Some plans will not re-authorize Prolia without documentation that supplementation is prescribed and the patient is adherent. Low serum calcium (hypocalcemia) is a contraindication to Prolia and must be corrected before each dose [4].

Follow-Up DXA Scanning

The International Society for Clinical Densitometry recommends repeat DXA scanning every one to two years when initiating or changing osteoporosis therapy [14]. Insurance plans routinely require an updated DXA result at the one- or two-year mark as part of continued authorization. The scan must show stable or improving BMD, or clinical documentation must explain why BMD declined despite adherence.

Dental Clearance

Osteonecrosis of the jaw (ONJ) is a rare but serious adverse effect of denosumab. The FDA label recommends a dental examination before initiating Prolia in patients with risk factors (poor oral hygiene, invasive dental procedures, concomitant corticosteroid use) [4]. Some plans request documentation of dental clearance as part of the PA package. Scheduling a dental exam before the first dose prevents this from becoming a surprise denial reason.

Original Clinical Framework: The ChristianaCare Prolia Coverage Checklist

The following five-point checklist is designed for ChristianaCare patients and their care teams to use before submitting a Prolia prior authorization request. Completing all five points before submission reduces the probability of a first-pass denial.

1. DXA documentation current. Confirm the most recent DXA report is dated within 24 months and lists T-scores at the lumbar spine, total hip, and femoral neck individually. A report that lists only "osteoporosis present" without numeric T-scores is routinely rejected.

2. Step-therapy record complete. If the plan requires a bisphosphonate trial, document the drug name, dose, duration, and reason for discontinuation (intolerance or inadequate response). "Patient preferred Prolia" is not an accepted reason on most plans.

3. FRAX score calculated and printed. Run the patient's FRAX score at shef.ac.uk/FRAX and attach the printout. A 10-year major osteoporotic fracture probability at or above 20 percent strengthens the medical necessity argument independent of T-score [11].

4. Calcium and vitamin D prescription on file. The prescribing provider must have a current order for calcium carbonate or calcium citrate plus vitamin D in the chart before submitting the PA. Missing this single element has triggered denials at multiple Delaware-area payers.

5. Correct J-code and diagnosis code pair. Use J0897 paired with M81.0 or M80.08 as appropriate. An M81.0 diagnosis on a patient with a documented fragility fracture should be coded M80.08 to capture the higher clinical severity. Miscoding downgrades medical necessity scores in automated utilization management systems.

Alternatives If Prolia Coverage Is Denied or Unaffordable

Not every patient will achieve coverage approval on the first or second attempt. Several clinically validated alternatives exist.

Oral Bisphosphonates

Alendronate (Fosamax) 70 mg weekly costs under $10 per month as a generic at most pharmacies. The Fracture Intervention Trial (FIT, N=2,027) demonstrated a 47 percent reduction in vertebral fracture risk over three years with alendronate versus placebo [15]. For patients who can tolerate oral bisphosphonates, this remains the most cost-accessible first-line option and satisfies step-therapy requirements for eventual Prolia approval.

Zoledronic Acid (Reclast)

Zoledronic acid 5 mg IV infused once annually is covered under Medicare Part B (J3488) and has a strong efficacy profile. The HORIZON Key Fracture Trial (N=7,765) showed a 70 percent reduction in morphometric vertebral fractures over three years (P<0.001) [16]. ChristianaCare outpatient infusion centers administer zoledronic acid, and the infusion visit itself is separately billable under Medicare Part B.

Romosozumab (Evenity)

For patients with very high fracture risk who cannot use Prolia or bisphosphonates, romosozumab 210 mg monthly (two subcutaneous injections) is an FDA-approved anabolic option. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48 percent compared with alendronate alone over 24 months [17]. Coverage criteria are stringent and typically require documented failure of or intolerance to at least one prior osteoporosis agent.